Overview
Investment Type
Venture Capital
Mentions in press and media 12
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 28, 2015 | Armune Bioscience Develops First Cancer-Specific Prostate Test | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Armune Bioscience, the Kalamazoo-based cancer diagnostic startup, has developed what it calls “the world’s only tumor-specific, non-PSA blood test designed to help doctors det... |
| Jul 6, 2012 | Alternative to PSA test for prostate cancer nears $1.5M financing target | A recent filing with the U.S. Securities and Exchange Commission reveals that Armune has raised almost all of a $1.5 million debt and other securities offering that started in 2009. A message left for President and CEO Eli Thomssen was not ... |
| Apr 11, 2012 | Using DNA to silence cancer-causing genes nets ProNAi $310K | In September 2010, the company advanced PNT2258 to a phase 1 trial for safety and tolerable dosage in patients with tumors for which there are no effective treatments. Results are expected later this year followed by the initiation of the n... |
| Feb 12, 2010 | Michigan biotech firm NephRx raises $6.2M for kidney, gastro disease therapies | It’s unclear from whom NephRx received the financing. However, its board members include employees of Michigan-based venture firms Seneca Partners and the Apjohn Group. NephRx executives didn’t immediately respond to requests for comment. T... |
| Sep 8, 2009 | Michigan dental device company Axenic raising $1 million | The company has raised about $250,000 of its $1 million, which Axenic is raising through dept and other options, according to the SEC. Previous investors include Apjohn Group, which co-founded the company. Promoted Clinical Care Capacity Pl... |
| Jul 16, 2009 | Michigan’s Aursos wants a bear-hug on bear-based osteoperosis drug | The 2-year-old company uses the parathyroid hormone proteins in black bears to strengthen bones. Company co-founder Seth Donahue gathered samples for initial tests by crawling into the caves of hibernating bears to draw their blood and det... |
| Michigan’s Aursos wants a bear-hug on bear-based osteoperosis drug | KALAMAZOO, Michigan — Something is stirring around Aursos, the sleepy biotech that uses proteins from black bears to develop an osteoporosis treatment. “We may no longer be around,” said Don Zinn, the company’s chief executive, saying onl... | |
| Using DNA to silence cancer-causing genes nets ProNAi $310K | A novel targeted cancer therapy may have a place in the multibillion-dollar cancer therapeutics market if it delivers positive results in an ongoing phase 1 clinical trial and attracts enough investor interest. Using nucleic acid-based DNA-... | |
| Michigan biotech firm NephRx raises $6.2M for kidney, gastro disease therapies | KALAMAZOO, Michigan — Biotechnology company NephRx Corp. has raised $6.2 million in equity for its kidney and gastrointestinal disease therapeutics, according to a Securities and Exchange Commission filing. The preclinical stage company is ... |
Show more
Reviews 0
FAQ about Apjohn Group
What has the press written about Apjohn Group?
Parsers VC has collected 12 articles mentioning Apjohn Group, among them “Armune Bioscience Develops First Cancer-Specific Prostate Test” (May 28, 2015) and “Alternative to PSA test for prostate cancer nears $1.5M financing target” (Jul 6, 2012).
Is Apjohn Group still active?
Yes, Apjohn Group is active; its latest activity on Parsers VC dates from Jan 26, 2018.